QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Repare Therapeutics Stock Price, News & Analysis (NASDAQ:RPTX)

$5.15
-0.12 (-2.28%)
(As of 11/30/2023 ET)
Compare
Today's Range
$5.11
$5.61
50-Day Range
$3.22
$12.70
52-Week Range
$3.08
$17.82
Volume
792,469 shs
Average Volume
173,316 shs
Market Capitalization
$216.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.80

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
323.3% Upside
$21.80 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Repare Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$7.48 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.99) to ($3.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

328th out of 949 stocks

Pharmaceutical Preparations Industry

136th out of 435 stocks


RPTX stock logo

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

RPTX Stock Price History

RPTX Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Recap: Repare Therapeutics Q3 Earnings
Repare Therapeutics Inc Ordinary Shares RPTX
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
See More Headlines
Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RPTX
Fax
N/A
Employees
180
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$21.80
High Stock Price Target
$28.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+310.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-29,050,000.00
Net Margins
-173.09%
Pretax Margin
-163.40%

Debt

Sales & Book Value

Annual Sales
$131.83 million
Book Value
$5.54 per share

Miscellaneous

Free Float
30,123,000
Market Cap
$223.71 million
Optionable
Not Optionable
Beta
0.09

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Lloyd Mitchell SegalMr. Lloyd Mitchell Segal (Age 59)
    President, CEO & Director
    Comp: $913.39k
  • Dr. Michael Zinda Ph.D. (Age 52)
    Executive VP & Chief Scientific Officer
    Comp: $641.53k
  • Dr. Maria Koehler M.D. (Age 66)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $682.8k
  • Dr. Daniel Durocher Ph.D.
    Co-Founder
  • Dr. Frank Sicheri Ph.D.
    Co-Founder
  • Dr. Agnel Sfeir Ph.D.
    Co-Founder
  • Mr. Steve Forte (Age 44)
    Executive VP & CFO
    Comp: $608.52k
  • Mr. Daniel Belanger
    Executive Vice President of Human Resource
  • Mr. Cameron Black
    Executive Vice President of Discovery
  • Dr. Kim A. Seth Ph.D.
    Executive VP & Chief Business Officer














RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RPTX shares.
View RPTX analyst ratings
or view top-rated stocks.

What is Repare Therapeutics' stock price target for 2024?

5 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $14.00 to $28.00. On average, they anticipate the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 323.3% from the stock's current price.
View analysts price targets for RPTX
or view top-rated stocks among Wall Street analysts.

How have RPTX shares performed in 2023?

Repare Therapeutics' stock was trading at $14.71 at the start of the year. Since then, RPTX stock has decreased by 65.0% and is now trading at $5.15.
View the best growth stocks for 2023 here
.

Are investors shorting Repare Therapeutics?

Repare Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 24.1% from the October 31st total of 1,740,000 shares. Based on an average daily trading volume, of 311,200 shares, the short-interest ratio is currently 6.9 days. Currently, 6.8% of the shares of the company are sold short.
View Repare Therapeutics' Short Interest
.

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RPTX earnings forecast
.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.41. The business had revenue of $2.16 million for the quarter, compared to analysts' expectations of $7.03 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 38.60% and a negative net margin of 173.09%.

What ETF holds Repare Therapeutics' stock ?

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and

When did Repare Therapeutics IPO?

(RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.23%), Redmile Group LLC (5.71%), FMR LLC (2.56%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), Harbor Capital Advisors Inc. (0.10%) and Trexquant Investment LP (0.07%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends
.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -